Pierrel SpA
MIL:PRL
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.73
1.745
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PRL stock under the Base Case scenario is 1.868 EUR. Compared to the current market price of 1.745 EUR, Pierrel SpA is Undervalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Pierrel SpA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PRL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Pierrel SpA
Balance Sheet Decomposition
Pierrel SpA
Current Assets | 17.6m |
Cash & Short-Term Investments | 4.8m |
Receivables | 5.2m |
Other Current Assets | 7.6m |
Non-Current Assets | 54.4m |
Long-Term Investments | 9.8k |
PP&E | 37.1m |
Intangibles | 12m |
Other Non-Current Assets | 5.3m |
Current Liabilities | 19.9m |
Accounts Payable | 8.2m |
Accrued Liabilities | 2.9m |
Other Current Liabilities | 8.8m |
Non-Current Liabilities | 26.3m |
Long-Term Debt | 21.2m |
Other Non-Current Liabilities | 5.2m |
Earnings Waterfall
Pierrel SpA
Revenue
|
33m
EUR
|
Cost of Revenue
|
-9.7m
EUR
|
Gross Profit
|
23.2m
EUR
|
Operating Expenses
|
-19.7m
EUR
|
Operating Income
|
3.5m
EUR
|
Other Expenses
|
-407.5k
EUR
|
Net Income
|
3.1m
EUR
|
Free Cash Flow Analysis
Pierrel SpA
EUR | |
Free Cash Flow | EUR |
PRL Profitability Score
Profitability Due Diligence
Pierrel SpA's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Pierrel SpA's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
PRL Solvency Score
Solvency Due Diligence
Pierrel SpA's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Pierrel SpA's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRL Price Targets Summary
Pierrel SpA
Dividends
Current shareholder yield for PRL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Pierrel SpA engages in the development, manufacturing, and marketing of medical therapies for the pharmaceutical, bio-pharmaceutical, and life science industries. The company is headquartered in Capua, Caserta. The company went IPO on 2006-05-23. The firm specializes in the pharmaceutical research, development and the manufacture of medicines. The company operates through three segments. The Contract Manufacturing segment covers research and development of various types of drugs, such as Tube vials, bottles, ampoules, drops, sprays, tablets and gels. The company manufactures the drugs in the production facility in Capua, which consists of warehouses, chemical and microbiological laboratories, offices and utilities buildings. The Pharma segment is active in the development, registration and licensing of new drugs and medical devices. The Tech-driven Contract Research & Development Organization segment provides research of existing drugs for the treatment of rare diseases, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one PRL stock under the Base Case scenario is 1.868 EUR.
Compared to the current market price of 1.745 EUR, Pierrel SpA is Undervalued by 7%.